Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Eyenovia, Inc. (EYEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1500+0.2000 (+10.26%)
At close: 04:00PM EDT
2.1500 0.00 (0.00%)
After hours: 07:59PM EDT
Advertisement

Eyenovia, Inc.

295 Madison Avenue
Suite 2400
New York, NY 10017
United States
917 289 1117
https://www.eyenovia.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Dr. Tsontcho Ianchulev M.D., M.P.H., MPHCo-Founder, Pres, Chief Medical Officer & Non-Exec. Chairman882.18kN/A1974
Mr. Michael M. RoweCEO & Director495.78kN/A1962
Mr. John P. Gandolfo CPACFO & Sec.549.45kN/A1961
Mr. Bren KernSr. VP of Manufacturing & OperationsN/AN/AN/A
Alexander LoboInvestor ContactN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

Eyenovia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement